Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Study Identifier
203818-004
CT.gov Identifier
NCT00381719
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Pain
    • Study Drug
  • AGN 203818
  • placebo capsule
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of diabetic peripheral neuropathy * Moderate to severe neuropathic pain
    Exclusion Criteria:
    * Any other uncontrolled disease * Pregnant or nursing females

    Protocol Summary

    This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy

    Study Locations

    Location
    Status
    Location
    Tacoma, Washington, United States
    Status
    Not applicable